Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study.

Apoorva Chawla,Douglas Adkins,Francis P. Worden,Krishna Rao,H. Shawn Hu,Katharine A. Price,Jose D Zavala,Theodore Karrison,Walter M. Stadler,Victoria Meucci Villaflor,Yves A. Lussier,Everett E. Vokes,Ezra E.W. Cohen,Tanguy Y. Seiwert

Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: Results of the randomized PII MAESTRO study.

2014

Apoorva Chawla
Douglas Adkins
Francis P. Worden
Krishna Rao
H. Shawn Hu
Katharine A. Price
Jose D Zavala
Theodore Karrison
Walter M. Stadler
Victoria Meucci Villaflor
Yves A. Lussier
Everett E. Vokes
Ezra E.W. Cohen
Tanguy Y. Seiwert

6089 Background: Patients with cetuximab resistant HNC have a median PFS of only 1.8 months (deSouza 2012). Preclinical/computational modelling suggests synergy between mTOR and EGFR, and potential...

Keywords:

Cetuximab
Cancer research
Physical therapy
Temsirolimus
Medicine
head and neck
Oncology
PI3K/AKT/mTOR pathway
Pathology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations